{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:01:35Z","timestamp":1761897695908},"reference-count":34,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OTT"],"DOI":"10.2147\/ott.s341120","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T05:50:06Z","timestamp":1647237006000},"page":"243-250","source":"Crossref","is-referenced-by-count":6,"title":["Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Michel","family":"Delforge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolien","family":"Raddoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corine","family":"Antonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Clement","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Kint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneleen","family":"Vanhellemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Bravetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","volume":"28","author":"Kumar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","volume":"22","author":"Anderson","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/ASHEDUCATION-2017.1.508","volume":"2017","author":"Sonneveld","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1091\/mbc.E12-01-0045","volume":"23","author":"Xu","year":"2012","journal-title":"Mol Biol Cell"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0412-4","volume":"10","author":"Camus","year":"2017","journal-title":"J Hematol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","volume":"18","author":"Gandhi","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00903-4","volume":"13","author":"Azizian","year":"2020","journal-title":"J Hematol Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-014-0085-1","volume":"7","author":"Gravina","year":"2014","journal-title":"J Hematol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"103504","DOI":"10.1016\/j.jprot.2019.103504","volume":"209","author":"Chanukuppa","year":"2019","journal-title":"J Proteomics"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1016\/S2352-3026(17)30143-6","volume":"4","author":"Bhutani","year":"2017","journal-title":"Lancet Haematol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/ajh.24451","volume":"91","author":"Jardin","year":"2016","journal-title":"Am J Hematol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.molcel.2011.11.022","volume":"45","author":"Golomb","year":"2012","journal-title":"Mol Cell"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1038\/leu.2013.172","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"78896","DOI":"10.18632\/oncotarget.12969","volume":"7","author":"Turner","year":"2016","journal-title":"Oncotarget"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"ref22","unstructured":"XPOVIO (Karyopharm Therapeutics Inc.): FDA package insert. Available from: https:\/\/medlibrary.org\/lib\/rx\/meds\/xpovio-1\/. Accessed February 1, 2021."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.clml.2019.12.026","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","volume":"34","author":"Gavriatopoulou","year":"2020","journal-title":"Leukemia"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref27","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) V5.0; 2017."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"30773","DOI":"10.18632\/oncotarget.25637","volume":"9","author":"Kashyap","year":"2018","journal-title":"Oncotarget"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e947","DOI":"10.1016\/j.clml.2020.07.016","volume":"20","author":"Magen","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1007\/s00277-020-04293-y","volume":"100","author":"Mouhieddine","year":"2021","journal-title":"Ann Hematol"},{"key":"ref31","unstructured":"Nexpovio-Union Register of medicinal products - Public health - European Commission. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1537.htm. Accessed May 20, 2021."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2019-124370","volume":"134","author":"White","year":"2019","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/BLOOD-2019-122907","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"8510","DOI":"10.1200\/jco.2020.38.15_suppl.8510","volume":"38","author":"Gasparetto","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["OncoTargets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=79064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=79064","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T05:50:12Z","timestamp":1647237012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/selinexor-bortezomib-and-dexamethasone-an-effective-salvage-regimen-fo-peer-reviewed-fulltext-article-OTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":34,"URL":"https:\/\/doi.org\/10.2147\/ott.s341120","relation":{},"ISSN":["1178-6930"],"issn-type":[{"value":"1178-6930","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}